Taysha Gene Therapies grants new hire 144,000 RSUs, 92,400 stock options priced at $5.78
Reuters2026/08/07 12:02- Taysha Gene Therapies granted a new employee 144,000 RSUs plus stock options for 92,400 shares under its 2023 Inducement Plan.
- RSUs vest in four equal annual installments starting on the first anniversary, subject to continued service.
- Options carry a $5.78 exercise price, a 10-year term, vesting over four years with 25% after one year.
- Remaining 75% of the options vest in equal monthly installments over the next 36 months, subject to continued service.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Preferred shares of South Korean companies are trading at a record 45% discount in ten years; Samsung's 110 trillion won buyback plan may help eliminate the "Korea discount"
Samsung Electronics' highly anticipated stock buyback plan is raising investor expectations that the South Korean giant will purchase non-voting preferred shares, narrowing their deep discount and setting a precedent for other companies.
A standout performer, privacy coins become the biggest winners in the crypto market this year
Crypto Zhong Liang: 9.8 BTC/ETH Market Perspective
PTPP nears completion of Rp 1.46 trillion Kataraja toll road section at 94.9%
Crypto prices
More
